Jenburkt Pharmaceuticals Limited

JENBURPH6

INE354A01013

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:31:01 05/07/2024 pm IST			5-day change	1st Jan Change
877.6 ^INR	-0.10%		+0.59%	+29.02%

28/05	Jenburkt Pharmaceuticals Limited Announces Board Retirements	CI
28/05	Jenburkt Pharmaceuticals Limited Announces Dividend	CI

Jenburkt Pharmaceuticals Limited Announces Resignation of Anjali S. Dalvi, Independent Director

February 07, 2020 at 04:26 pm IST

Jenburkt Pharmaceuticals Limited announced that Ms. Anjali S. Dalvi, independent director of the company have tendered her resignation, at the board meeting held on 7 February, 2020, to be effective immediately.

Latest news about Jenburkt Pharmaceuticals Limited

Jenburkt Pharmaceuticals Limited Announces Board Retirements	28/05	CI
Jenburkt Pharmaceuticals Limited Announces Dividend	28/05	CI
Jenburkt Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	28/05	CI
Jenburkt Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	06/02	CI
Jenburkt Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	07/11	CI
Jenburkt Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	08/23/08	CI
Jenburkt Pharmaceuticals Limited Appoints Sumit Ajaybhai Thakkar as A Non-Executive and Independent Director	27/23/27	CI
Jenburkt Pharmaceuticals Limited Appoints Sumit Ajaybhai Thakkar as Non-Executive Independent Director	27/23/27	CI
Jenburkt Pharmaceuticals Limited Approves Dividend for the Financial Year Ended 31 March, 2023	26/23/26	CI
Jenburkt Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23/23/23	CI
Jenburkt Pharmaceuticals Limited Approves Dividend	23/23/23	CI
Tranche Update on Jenburkt Pharmaceuticals Limited's Equity Buyback Plan announced on December 1, 2022.	24/23/24	CI
Jenburkt Pharmaceuticals Limited's Equity Buyback announced on December 1, 2022, has closed with repurchase of 176,078 shares, representing 3.84% for INR 114.24 million.	24/23/24	CI
Jenburkt Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	07/23/07	CI
Jenburkt Pharmaceuticals Limited announces an Equity Buyback for INR 116 million worth of its shares.	01/22/01	CI
Jenburkt Pharmaceuticals Limited authorizes a Buyback Plan.	01/22/01	CI
Jenburkt Pharmaceuticals Board to Consider Share Buyback	29/22/29	MT
Jenburkt Pharmaceuticals Limited's Board intends to launch an Equity Buyback on December 1, 2022.	28/22/28	CI
Jenburkt Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	08/22/08	CI
Jenburkt Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	01/22/01	CI
Jenburkt Pharmaceuticals Limited Approves Dividend for the Financial Year Ended March 31, 2022	30/22/30	CI
Jenburkt Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2022	27/22/27	CI
Jenburkt Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	27/22/27	CI
Jenburkt Pharmaceuticals Limited Approves Dividend	27/22/27	CI
Jenburkt Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	12/22/12	CI

Chart Jenburkt Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

Jenburkt Pharmaceuticals Limited is an India-based company that is engaged in the business of manufacturing, producing, developing and marketing a range of branded pharmaceuticals and health care products. The Company offers pharmaceutical products for various therapeutic areas, analgesic and antipyretics anthelmintics, anti-arthritic, anti-diabetics, anti-infectives, antifungals, antimalarials, antiulcerants/antacids, aphrodisiac, consumer division, cough and cold, muscle relaxants neuropathic pain, nutraceuticals and pain management. The Company's product brands include Allerzine tablets, Cartisafe forte MSM tablets, Eberjen Cream and SOL, ECOPROT powder, Frendacid suspension, Fundu tablets, Glajen-E capsules, GLUCOTROL tablets, Jenflam tablets, Lutriben cream, Ornel tablets, Pantazole tablets and others. The Company's manufacturing plant is located in Sihor-Gujarat. The Company's products are exported to approximately 13 countries globally.

Sector

Pharmaceuticals

Calendar

23/07/2024 - Détachement de for final dividend

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JENBURKT PHARMACEUTICALS LIMITED	+29.02%	46.39M
ELI LILLY AND COMPANY	+56.89%	823B
NOVO NORDISK A/S	+39.52%	627B
JOHNSON & JOHNSON	-6.55%	353B
MERCK & CO., INC.	+15.99%	320B
ABBVIE INC.	+7.92%	295B
ASTRAZENECA PLC	+13.74%	239B
NOVARTIS AG	+13.83%	220B
ROCHE HOLDING AG	-0.49%	219B
AMGEN INC.	+7.94%	167B